PC / City
+49 9221 82762-0
+49 9221 82762-99
Roche Kulmbach GmbH is Roche's Center of Excellence for the discovery and development of new therapeutics on the basis of ribonucleic acids (RNA). Currently, Roche Kulmbach GmbH focuses on a new class of therapeutics based on the principle of RNA interference (RNAi). RNAi is a natural process to selectively silence endogenous genes and is mediated by small interfering RNAs (siRNAs). Roche Kulmbach GmbH uses synthetic siRNAs to specifically silence disease-associated genes. This universal approach is applied to develop novel therapeutics for the treatment of oncological, respiratory and metabolic diseases.
Roche Kulmbach GmbH was the first company worldwide to focus on the therapeutic potential of RNA interference. Scientists at Roche Kulmbach AG have excellent know-how about the discovery and development of RNAi therapeutics, propelled by the experience gained from 2003-2007 when they were part of the Alnylam Pharmaceuticals organization, a world-leading company in RNAi.
Key sectors / sub-sectors
- Biotechnology: Technical services for biotechnology
- Biotechnology: Therapeutic drug development
- Research and experimental development on biotechnology 72.11
Sales markets - target industries
Sales markets - target countries